Answers · IP Strategy & Portfolio
How many patents does my company actually need?
Updated June 2026
The short answer
For most early and growth-stage companies, 5 to 15 well-chosen patent families are enough to cover the inventions that actually drive revenue. A commonly cited planning benchmark puts annual patent spend near 1 percent of R&D, which is a budget heuristic rather than a count, and that is the right way around: the number you need follows from products, competitors, and exit plans, never from a quota.
Companies holding thousands of patents are playing a different game, accumulating negotiating mass for cross-licensing in dense fields like semiconductors and telecom. Unless that is your field, their counts are the wrong benchmark.
Three questions that set the number
First, where does revenue concentrate? Each product or platform that carries material revenue typically justifies coverage of its core mechanism plus the obvious variations a competitor would try. Second, what can competitors design around? A single patent on one implementation invites a workaround; the count grows where design-around paths are cheap and shrinks where the core invention is hard to avoid. Third, who has to be impressed later? An acquirer's diligence team checks whether the patents cover the products being bought, and a portfolio of three assets that map cleanly to revenue reads better than thirty that map to abandoned projects.
Answer those three and the count falls out. In our engagements the answer for a focused company is usually a single-digit or low-double-digit number of families, grown deliberately as products and markets multiply.
Rules of thumb, held loosely
A flagship product is often well covered by three to five families: the core invention, the strongest improvements, and the design-arounds a competitor would otherwise use as exits. The 1 percent of R&D budget benchmark is commonly cited and a reasonable sanity check, though capital-intensive and litigation-heavy sectors run higher. International protection multiplies cost rather than count: published estimates commonly put broad foreign protection at 10 to 15 times the cost of US-only filing for the same family, which is why jurisdiction strategy matters more than raw filing volume.
Treat all of these as cross-checks on a business-driven plan, never as targets. A quota produces filings that exist to hit the quota.
Signals you are over or under
Signs of too many: maintenance fees on patents no current product uses, filings nobody can map to a revenue line, and a renewal budget that grows while the product line does not. Published analyses suggest roughly half of US patents lapse before full term, which is what unmanaged accumulation eventually looks like.
Signs of too few: competitors filing actively in your core technology while you are absent, a flagship product protected by a single patent, or an investor diligence list you cannot answer. A landscape analysis against named competitors is the fastest way to see which side of the line you are on.
Related questions
Is one patent enough to raise a funding round?
Often, if it covers the core of what investors are buying into. Published research has associated patent holdings with meaningfully higher odds of raising venture funding, and the effect comes from coverage of the core technology rather than from the count.
Should we match our biggest competitor's filing count?
Match their coverage where it threatens you, never their volume. A large competitor's count includes decades of legacy filings and defensive mass. The actionable question is whether their recent filings sit on top of your roadmap, which a landscape analysis answers directly.
Do provisional applications count toward the number?
Count families, anchored by the filings you intend to complete. Provisionals are placeholders that expire in 12 months unless converted, so a stack of unconverted provisionals is a to-do list rather than a portfolio.
When do we stop adding patents?
You never exactly stop; you rebalance. Annual portfolio review should retire filings that no longer map to products while adding coverage where the roadmap and competitor activity have moved. The count can stay flat while the portfolio improves.
Get a number tied to your business
A short discovery conversation about your products, competitors, and plans is usually enough to bracket the right portfolio size and budget. The call is free.
Talk with Our TeamRelated
ipCapital Group is a consultancy, not a law firm, and nothing on this page is legal advice. Dollar figures on this page are typical market ranges for professional IP services, drawn from published sources and industry experience across a variety of providers. They are not an ipCG quote or rate card; every ipCG engagement is individually scoped and priced. See how our pricing works.